3.68
Maravai Lifesciences Holdings Inc stock is traded at $3.68, with a volume of 877.45K.
It is down -3.66% in the last 24 hours and up +19.09% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$3.82
Open:
$3.73
24h Volume:
877.45K
Relative Volume:
0.75
Market Cap:
$533.68M
Revenue:
$185.74M
Net Income/Loss:
$-230.76M
P/E Ratio:
-4.0623
EPS:
-0.9059
Net Cash Flow:
$-70.72M
1W Performance:
+3.37%
1M Performance:
+19.09%
6M Performance:
+46.61%
1Y Performance:
+30.96%
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings Inc
|
3.68 | 553.99M | 185.74M | -230.76M | -70.72M | -0.9059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Royce & Associates LP Has $5.06 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
First Eagle Investment Management LLC Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
MRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Maravai Lifesciences Charts Early Turnaround in 2025 - TipRanks
Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpStill a Buy? - MarketBeat
Is Maravai LifeSciences Holdings Inc.’s ROE strong enoughMarket Growth Report & Fast Exit and Entry Trade Guides - mfd.ru
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts - Investing.com Nigeria
Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives - Sahm
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Maravai LifeSciences Q4 Earnings Call Highlights - MarketBeat
Maravai LifeSciences Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-02-26 - Seeking Alpha
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q4 2025 beats EPS forecast, stock jumps 4.5% - Investing.com Canada
MRVI: 2025 saw revenue beat, margin recovery, and strong 2026 growth and profitability guidance - TradingView
Maravai LifeSciences Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
MRVI Projects FY26 Adjusted EBITDA Between $18M and $20M - GuruFocus
Maravai LifeSciences (MRVI) Surpasses Revenue Expectations in Q4 - GuruFocus
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound - Stock Titan
Maravai LifeSciences Q4 2025 Earnings Call Transcript - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
What are Maravai LifeSciences Holdings Inc.’s growth levers2025 Geopolitical Influence & Weekly High Return Stock Opportunities - mfd.ru
Maravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Monaco Asset Management SAM - MarketBeat
Value Recap: What is the PEG ratio of Maravai LifeSciences Holdings IncEarnings Overview Report & Daily Entry Point Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings (MRVI) Investor Outlook: Navigating a 27.55% Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
12 West Capital (NASDAQ: MRVI) discloses 6.2% beneficial stake in Maravai - Stock Titan
Is There An Opportunity With Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 34% Undervaluation? - Yahoo Finance
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Hold" by Brokerages - MarketBeat
MRVI Should I Buy - Intellectia AI
Market Moves: Will REFI face regulatory challengesWeekly Investment Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake - Stock Titan
Options Flow: Will Cohen Company Inc face regulatory challengesQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Gainers Report: Is Maravai LifeSciences Holdings Incs ROE strong enough2025 Buyback Activity & Smart Swing Trading Techniques - baoquankhu1.vn
Maravai to Announce Q4 and Full Year 2025 Results - Intellectia AI
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026 - Business Wire
What MACD trends signal for Maravai LifeSciences Holdings Inc. (MAR) stockQuarterly Trade Review & Reliable Breakout Stock Forecasts - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out - ACCESS Newswire
Growth Report: Is Tourmaline Bio Inc a speculative investmentProduct Launch & AI Powered Market Entry Strategies - baoquankhu1.vn
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):